forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

• Status: Terminated
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Monash University
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

Patients with Type 2 Diabetes who are:

• Prescribed Forxiga for glycaemic management AND

• Who have the ability to provide informed consent

Exclusion Criteria:

Patients with whom use of Forxiga is contraindicated:

• Patients with Type 1 Diabetes

• Patients with moderate to severe renal impairment [Creatinine clearance (CrCl) <60 mL/min or estimated glomerular filtration rate (eGFR) <60mL/min/1.73m²]

Additional exclusion criteria:

• Age >75 years

• Concomitant use of loop diuretics or pioglitazone

• Patients who are currently on another SGLT2 inhibitor